Innovative PolyStyreneLoop Plant Will Recycle Polystyrene Foam Demolition Waste and Recover Valuable Resources
3.6.2021 09:00:00 EEST | Business Wire | Press release
A new recycling plant in the Netherlands will recycle expanded polystyrene (EPS) demolition waste and also handle a legacy additive.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005924/en/
An aerial view of the PolystyreneLoop recycling plant in Terneuzen, the Netherlands. (Photo: Business Wire)
The PolyStyreneLoop recycling plant in Terneuzen, Netherlands, is scheduled to open on the 16th of June. The plant was built to prove the technical and economic feasibility of a large-scale, closed-loop solution for the recycling of EPS waste.
The PolyStyreneLoop facility will recycle EPS insulation using a physical recycling process based on the CreaSolv® Technology. This technology will turn EPS foam demolition waste from building and construction insulation (B&C) from the Netherlands, Germany and other countries into new high quality raw material. All kinds of impurities, such as cement or other construction residues, as well as the legacy additive HBCD, will be safely removed and valuable bromine recovered.
“This plant showcases how the EPS industry is always looking for ways to boost its recycling capabilities,” said Lein Tange, Co-Director of PolyStyreneLoop. “The purpose of this plant is to pave the way for the construction of similar EPS recycling plants in the rest of Europe.”
The legal structure of the plant, which benefited from a European Union LIFE programme grant, was also unique. It has been built by the PolyStyreneLoop Cooperative, a Dutch non-profit organisation whose members comprise more than 70 industry representatives from the whole polystyrene foam value chain.
The Terneuzen plant will have the capacity to recycle 3,300 metric tonnes of polystyrene foam demolition waste coming from B&C per year, validating the technical, economic, and environmental viability of a new recycling process in which polystyrene foams containing HBCD can be fully integrated in the circular economy rather than being lost from circularity.
“It’s a real plus that the plant can not only take care of current recycling waste but also legacy recycling waste,” said Jan Noordegraaf, co-director of the plant. “Moreover, we can do this with about the same energy input as mechanical recycling and the energy we use comes solely from windmills.”
The PSLoop plant will demonstrate the possibility of infinite recycling of EPS B&C waste. Later, it will also recycle extruded polystyrene, or XPS, also known as StyrofoamTM.
EPS is a lightweight foam composed of 98% air and 2% technology with outstanding protective and thermal insulation properties. In addition to building and road construction uses, it is widely used in packaging to protect everything from heavy white goods to sensitive electronics, fresh fruit and vegetables, vaccines and even bees.
About PolyStyreneLoop
PolyStyreneLoop is a cooperative representing more than 70 companies from the polystyrene foam value chain. Its members include includes polystyrene raw material producers, foam manufacturers, additives suppliers, foam converters and recyclers as well as EUMEPS, the association and voice of European Manufacturers of Expanded Polystyrene.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005924/en/
Contact information
Lein Tange, Director
info@polystyreneloop.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom